NewsRoom Articles - Page 93 of 154 - PsychedelicNewsWire (PNW)

ThursdayJun 24, 2021 3:18 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

ThursdayJun 24, 2021 12:00 pm

Researchers Find That Mindfulness Meditation Boosts Psilocybin’s Beneficial Effects

In the recent past, numerous studies have focused on the clinical application of psychedelics, including LSD, ayahuasca and psilocybin, in treating anxiety and depression disorders being conducted. For example, University of Zurich researchers have demonstrated that mindfulness meditation can improve the positive long-term effects of an individual dose of psilocybin, which can be found in magic mushrooms. Psilocybin, which is the primary active ingredient in hallucinogenic mushrooms, and LSD are known to alter the perception of individuals who consume them as well as induce feelings of unity and bliss. These experiences of decreased self-focus and self-transcendence are similar to those…

WednesdayJun 23, 2021 1:45 pm

Proposed New York Legislation Seeks to Set Up Psychedelics Research Institute

At the start of this month, Linda Rosenthal, an Assemblywoman of the state of New York, introduced legislation that calls for the state to establish a research institute to study the therapeutic potential of psychedelic substances for individuals who are afflicted with a substance use disorder, including opioids and methamphetamine, among other substances. The institute would be managed and run by the state. Under the program, researchers would create an advisory board that would offer oversight of clinical trials and aid principal researchers at sites that lacked formal review board oversight as well as set up training programs for professionals…

TuesdayJun 22, 2021 9:45 am

Could Psychedelics Be Used to Understand Near-Death Experiences?

For decades now, researchers have been unable to decipher what exactly causes a near-death experience. While most scientific studies haven’t delved into the study of near-death experiences, researchers have discovered that the characteristics of these incidents remain constant 20 years after they occurred. This discovery offers researchers an opportunity to learn more about these incidents first-hand and call attention to the foundational characteristics of near-death experiences. A recent study found that near-death experiences were marked by the infamous tunnel of light, an out-of-body experience and a feeling of inner peace. Additionally, scientists are discovering that psychedelics may play a big…

MondayJun 21, 2021 1:15 pm

Researchers ID Psychedelic Analog That Counters Effects of Stress in Mice

New research conducted by researchers from the University of California-Santa Cruz has found that an individual dose of tabernanthalog (“TBG”) can repair neural circuits in the brain that are damaged by stress, enhance neuronal connection regrowth and remedy behavioral deficits such as cognitive inflexibility and anxiety that are caused by stress. TBG is a new compound that has a structure similar to ibogaine, a psychedelic drug. Prior studies have found that while ibogaine has the potential to treat addiction, it is also a powerful hallucinogen and can cause severe heart arrhythmias. However, unlike ibogaine, TBG lacks hallucinogenic and toxic effects.…

FridayJun 18, 2021 2:45 pm

Mike Tyson Asserts That Psilocybin Helped Change His Life

Towards the end of last year, Mike Tyson took on Ray Jones Jr. in a boxing match for the first time in more than a decade. In a pay-per-view exhibition, the two boxed, ending the eight-round fight 78 to 74 for Tyson. During an interview with Reuters, Mike Tyson, commonly known as Iron Mike, revealed that he had struggled with drug addiction in his life, asserting that the use of psilocybin helped him get back on his feet. He explained that once he was introduced to psilocybin mushrooms, his whole life changed, adding that the shrooms had helped him when…

ThursdayJun 17, 2021 2:45 pm

Scientists Study Psychopathology Through Social Dominance Lens

A report published recently in PLOS One revealed that the symptoms of mental health conditions affected how individuals responded to being placed in subordinate and dominant positions. The research stated that depressive and manic symptoms especially were linked to physiological and psychological responses to social dominance. CALM Program director Sheri Johnson, who is also a University of California psychology professor and the author of the study, stated that she had collaborated with her associates to review the literature on psychopathology and social dominance. Johnson explained that there were various studies suggesting how important social dominance was to various forms of…

ThursdayJun 17, 2021 10:54 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking…

WednesdayJun 16, 2021 10:39 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating disorders expert Jennifer Miller, M.D. at the University of Florida The trial will focus on Tryp’s flagship candidate, TRP-8802, in treating binge eating and hypothalamic obesity The company expects to begin manufacturing its…

WednesdayJun 16, 2021 9:30 am

Coronavirus Pandemic Prompts Increases in Eating Disorders Among Adults, Teenagers

Eating disorders affect about 9% of individuals across the globe. Data from the National Association of Anorexia Nervosa and Associated Disorders shows that eating disorders cause nearly 10,000 deaths in the United States annually and impact roughly 30 million individuals. Physicians and other specialists have observed an increase in the numbers of patients seeking help for eating disorders, noting that the pandemic has prompted an increase in the number of eating disorders as well as relapses. Jennifer Wildes, the director of the University of Chicago’s outpatient eating disorders program, stated that the program had recorded significant increases. Wildes, who is…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000